Oncolytic Virotherapy: A Contest between Apples and Oranges

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1107-1116

  Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

Author keywords

competitive landscape; oncolytic virotherapy; T VEC; viro immuno oncology

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCYTOSINE; FLUOROURACIL; GLUCOCORTICOID; IPILIMUMAB; METHOTREXATE; MYCOPHENOLIC ACID; TALIMOGENE LAHERPAREPVEC; VEMURAFENIB; VOCIMAGENE AMIRETROREPVEC; CHIMERIC PROTEIN; ONCOLYTIC VIRUS; TUMOR ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN CANCER; DRUG APPROVAL; HUMAN; IMMUNE RESPONSE; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VIROTHERAPY; ANTIGEN PRESENTATION; CHEMISTRY; GENE VECTOR; GENETICS; HUMAN ALPHAHERPESVIRUS 1; IMMUNOLOGY; LYMPH NODE; MEASLES VIRUS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PLASMACYTOMA; PROCEDURES; SKIN TUMOR; T LYMPHOCYTE; TRENDS;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; LYMPH NODES; MEASLES VIRUS; MELANOMA; MULTIPLE MYELOMA; MUTANT CHIMERIC PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PLASMACYTOMA; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 85017113587     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.026     Document Type: Review

References (100)

1. 1 Russell, S.J., Peng, K.W., Bell, J.C., Oncolytic virotherapy. Nat. Biotechnol. 30 (2012), 658–670.
2. 2 Seymour, L.W., Fisher, K.D., Oncolytic viruses: finally delivering. Br. J. Cancer 114 (2016), 357–361.
3. 3 Rehman, H., Silk, A.W., Kane, M.P., Kaufman, H.L., Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer, 4, 2016, 53.
4. 4 Bommareddy, P.K., Patel, A., Hossain, S., Kaufman, H.L., Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am. J. Clin. Dermatol. 18 (2017), 1–15.
5. 5 Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33 (2015), 2780–2788.
6. 6 Puzanov, I., Milhem, M.M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K.S., Anderson, A., Chou, J., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34 (2016), 2619–2626.
7. 7 Long, G.V., Dummer, R., Ribas, A., Puzanov, I., VanderWalde, A., Andtbacka, R.H.I., Michielin, O., Olszanski, A.J., Malvehy, J., Cebon, J.S., et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene lapherparevec (T-VEC) and pembrolizuman (pembro) for unresectable stage IIIB-IV melanoma. J. Clin. Oncol., 34(Suppl.; abstr. 9568), 2016.
8. 8 Kelly, E., Russell, S.J., History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15 (2007), 651–659.
9. 9 Maroun, J., Muñoz-Alía, M., Ammayappan, A., Schulze, A., Peng, K.-W., Russell, S., Designing and building oncolytic viruses. Future Virol., 2017, 10.2217/fvl-2016-0129 Published online March 31, 2017.
10. 10 Keller, B.A., Bell, J.C., Oncolytic viruses—immunotherapeutics on the rise. J. Mol. Med. (Berl.) 94 (2016), 979–991.
11. 11 Lawler, S.E., Speranza, M.C., Cho, C.F., Chiocca, E.A., Oncolytic viruses in cancer treatment: a review. JAMA Oncol., 2016, 10.1001/jamaoncol.2016.2064 Published July 21, 2016.
12. 12 Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M., Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 (1991), 854–856.
13. 13 Wilcox, D.R., Longnecker, R., The herpes simplex virus neurovirulence factor γ34.5: revealing virus-host interactions. PLoS Pathog., 12, 2016, e1005449.
14. 14 Kaur, B., Chiocca, E.A., Cripe, T.P., Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr. Pharm. Biotechnol. 13 (2012), 1842–1851.
15. 15 Liu, B.L., Robinson, M., Han, Z.Q., Branston, R.H., English, C., Reay, P., McGrath, Y., Thomas, S.K., Thornton, M., Bullock, P., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10 (2003), 292–303.
16. 16 Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S., Kim-Schulze, S., Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17 (2010), 718–730.
17. 17 Kohlhapp, F.J., Kaufman, H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 22 (2016), 1048–1054.
18. 18 Hong, C.S., Fellows, W., Niranjan, A., Alber, S., Watkins, S., Cohen, J.B., Glorioso, J.C., Grandi, P., Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 17 (2010), 1200–1205.
19. 19 Nakamori, M., Fu, X., Meng, F., Jin, A., Tao, L., Bast, R.C. Jr., Zhang, X., Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin. Cancer Res. 9 (2003), 2727–2733.
20. 20 Simpson, G.R., Coffin, R.S., Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control. Methods Mol. Biol. 542 (2009), 551–564.
21. 21 Menotti, L., Cerretani, A., Hengel, H., Campadelli-Fiume, G., Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J. Virol. 82 (2008), 10153–10161.
22. 22 Goins, W.F., Hall, B., Cohen, J.B., Glorioso, J.C., Retargeting of herpes simplex virus (HSV) vectors. Curr. Opin. Virol. 21 (2016), 93–101.
23. 23 Lee, C.Y., Rennie, P.S., Jia, W.W., MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin. Cancer Res. 15 (2009), 5126–5135.
24. 24 Mazzacurati, L., Marzulli, M., Reinhart, B., Miyagawa, Y., Uchida, H., Goins, W.F., Li, A., Kaur, B., Caligiuri, M., Cripe, T., et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol. Ther. 23 (2015), 99–107.
25. 25 Kambara, H., Okano, H., Chiocca, E.A., Saeki, Y., An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65 (2005), 2832–2839.
26. 26 Yoo, J.Y., Haseley, A., Bratasz, A., Chiocca, E.A., Zhang, J., Powell, K., Kaur, B., Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and “Vstat120”-expressing oncolytic virus. Mol. Ther. 20 (2012), 287–297.
27. 27 Foreman, P.M., Friedman, G.K., Cassady, K.A., Markert, J.M., Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics, 2017, 10.1007/s13311-017-0516-0 Published March 6, 2017.
28. 28 Goetz, C., Dobrikova, E., Shveygert, M., Dobrikov, M., Gromeier, M., Oncolytic poliovirus against malignant glioma. Future Virol. 6 (2011), 1045–1058.
29. 29 Cloughesy, T.F., Landolfi, J., Hogan, D.J., Bloomfield, S., Carter, B., Chen, C.C., Elder, J.B., Kalkanis, S.N., Kesari, S., Lai, A., et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci. Transl. Med., 8, 2016, 341ra75.
30. 30 Lang, F., Conrad, C., Gomez-Manzano, C.D., Tufaro, F., Yung, W., Sawaya, R., Weinberg, J., Prabhu, S., Fuller, G., Aldape, K., Fueyo, J., First-in-human phase I clinical trial of oncolytic delta-24-RGD (DNX-2401) with biological endpoints: Implications for viro-immunotherapy. Neuro Oncol., 16(Suppl. 3), 2014, iii39.
31. 31 Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J.R., Leuchs, B., Dahm, M., Krebs, O., von Knebel Doeberitz, M., Huber, B., Hajda, J., Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer, 12, 2012, 99.
32. 32 Xia, Z.J., Chang, J.H., Zhang, L., Jiang, W.Q., Guan, Z.Z., Liu, J.W., Zhang, Y., Hu, X.H., Wu, G.H., Wang, H.Q., et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Chin. J. Cancer 23 (2004), 1666–1670.
33. 33 Yu, W., Fang, H., Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7 (2007), 141–148.
34. 34 Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19 (2013), 329–336.
35. 35 Chentoufi, A.A., Benmohamed, L., Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin. Dev. Immunol., 2012, 2012, 149135.
36. 36 Andtbacka, R.H.I., Ross, M.I., Agarwala, S.S., Taylor, M.H., Vetto, J.T., Neves, R.I., Daud, A., Khong, H.T., Ungerleider, R.S., Boran, A.D.W., et al. Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma. J. Clin. Oncol., 34(Suppl.; abstract 9543), 2016.
37. 37 Miller, A., Russell, S.J., The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin. Biol. Ther. 16 (2016), 15–32.
38. 38 Smith, J.S., Robinson, N.J., Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186:Suppl 1 (2002), S3–S28.
39. 39 Xu, F., Schillinger, J.A., Sternberg, M.R., Johnson, R.E., Lee, F.K., Nahmias, A.J., Markowitz, L.E., Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J. Infect. Dis. 185 (2002), 1019–1024.
40. 40 Virgin, S., Pathogenesis of viral infection. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, Volume 1, 2007, Lippincott, Williams and Wilkins, Philadelphia, PA, 327–388.
41. 41 Griffin, D.E., Measles virus. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, Volume 2, 2007, Lippincott, Williams and Wilkins, Philadelphia, PA, 1551–1586.
42. 42 Zingher, A., Mortimer, P., Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187. Rev. Med. Virol. 15 (2005), 407–418.
43. 43 Moore, A.E., The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 2 (1949), 525–534.
44. 44 Naik, S., Nace, R., Federspiel, M.J., Barber, G.N., Peng, K.W., Russell, S.J., Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26 (2012), 1870–1878.
45. 45 Phuangsab, A., Lorence, R.M., Reichard, K.W., Peeples, M.E., Walter, R.J., Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 172 (2001), 27–36.
46. 46 Ruiz, A.J., Hadac, E.M., Nace, R.A., Russell, S.J., MicroRNA-detargeted mengovirus for oncolytic virotherapy. J. Virol. 90 (2016), 4078–4092.
47. 47 Au, G.G., Lindberg, A.M., Barry, R.D., Shafren, D.R., Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol. 26 (2005), 1471–1476.
48. 48 McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., Bartlett, D.L., Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61 (2001), 8751–8757.
49. 49 Yu, L., Baxter, P.A., Zhao, X., Liu, Z., Wadhwa, L., Zhang, Y., Su, J.M., Tan, X., Yang, J., Adesina, A., et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 13 (2011), 14–27.
50. 50 Bailey, K., Kirk, A., Naik, S., Nace, R., Steele, M.B., Suksanpaisan, L., Li, X., Federspiel, M.J., Peng, K.W., Kirk, D., Russell, S.J., Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PLoS ONE, 8, 2013, e73759.
51. 51 Miller, A., Suksanpaisan, L., Naik, S., Nace, R., Federspiel, M., Peng, K.W., Russell, S.J., Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Mol. Ther. Oncolytics, 1, 2014, 14005.
52. 52 Breitbach, C.J., De Silva, N.S., Falls, T.J., Aladl, U., Evgin, L., Paterson, J., Sun, Y.Y., Roy, D.G., Rintoul, J.L., Daneshmand, M., et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19 (2011), 886–894.
53. 53 Breitbach, C.J., Arulanandam, R., De Silva, N., Thorne, S.H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T.H., et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73 (2013), 1265–1275.
54. 54 Benencia, F., Courreges, M.C., Conejo-García, J.R., Buckanovich, R.J., Zhang, L., Carroll, R.H., Morgan, M.A., Coukos, G., Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum. Gene Ther. 16 (2005), 765–778.
55. 55 Kelly, E.J., Hadac, E.M., Cullen, B.R., Russell, S.J., MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog., 6, 2010, e1000820.
56. 56 Power, A.T., Wang, J., Falls, T.J., Paterson, J.M., Parato, K.A., Lichty, B.D., Stojdl, D.F., Forsyth, P.A., Atkins, H., Bell, J.C., Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15 (2007), 123–130.
57. 57 Liu, C., Suksanpaisan, L., Chen, Y.W., Russell, S.J., Peng, K.W., Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp. Hematol. 41 (2013), 508–517.
58. 58 Mader, E.K., Maeyama, Y., Lin, Y., Butler, G.W., Russell, H.M., Galanis, E., Russell, S.J., Dietz, A.B., Peng, K.W., Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 15 (2009), 7246–7255.
59. 59 Mader, E.K., Butler, G., Dowdy, S.C., Mariani, A., Knutson, K.L., Federspiel, M.J., Russell, S.J., Galanis, E., Dietz, A.B., Peng, K.W., Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J. Transl. Med., 11, 2013, 20.
60. 60 Ruiz, A.J., Russell, S.J., MicroRNAs and oncolytic viruses. Curr. Opin. Virol. 13 (2015), 40–48.
61. 61 Russell, S.J., Peng, K.W., Viruses as anticancer drugs. Trends Pharmacol. Sci. 28 (2007), 326–333.
62. 62 Thorne, S.H., Hermiston, T., Kirn, D., Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol. 32 (2005), 537–548.
63. 63 Dorer, D.E., Nettelbeck, D.M., Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 61 (2009), 554–571.
64. 64 Beatty, M.S., Curiel, D.T., Chapter two–Adenovirus strategies for tissue-specific targeting. Adv. Cancer Res. 115 (2012), 39–67.
65. 65 Nakamura, T., Russell, S.J., Oncolytic measles viruses for cancer therapy. Expert Opin. Biol. Ther. 4 (2004), 1685–1692.
66. 66 Ilkow, C.S., Swift, S.L., Bell, J.C., Diallo, J.S., From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog., 10, 2014, e1003836.
67. 67 Russell, S.J., Federspiel, M.J., Peng, K.W., Tong, C., Dingli, D., Morice, W.G., Lowe, V., O'Connor, M.K., Kyle, R.A., Leung, N., et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89 (2014), 926–933.
68. 68 Langfield, K.K., Walker, H.J., Gregory, L.C., Federspiel, M.J., Manufacture of measles viruses. Methods Mol. Biol. 737 (2011), 345–366.
69. 69 Breitbach, C.J., Burke, J., Jonker, D., Stephenson, J., Haas, A.R., Chow, L.Q., Nieva, J., Hwang, T.H., Moon, A., Patt, R., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477 (2011), 99–102.
70. 70 Kelly, E.J., Hadac, E.M., Greiner, S., Russell, S.J., Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14 (2008), 1278–1283.
71. 71 Strassburg, M.A., The global eradication of smallpox. Am. J. Infect. Control 10 (1982), 53–59.
72. 72 Letchworth, G.J., Rodriguez, L.L., Del cbarrera, J., Vesicular stomatitis. Vet. J. 157 (1999), 239–260.
73. 73 Lambright, E.S., Kang, E.H., Force, S., Lanuti, M., Caparrelli, D., Kaiser, L.R., Albelda, S.M., Molnar-Kimber, K.L., Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol. Ther. 2 (2000), 387–393.
74. 74 Ilett, E.J., Bárcena, M., Errington-Mais, F., Griffin, S., Harrington, K.J., Pandha, H.S., Coffey, M., Selby, P.J., Limpens, R.W., Mommaas, M., et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin. Cancer Res. 17 (2011), 2767–2776.
75. 75 Nakashima, H., Nguyen, T., Chiocca, E.A., Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virother. 4 (2015), 183–191.
76. 76 Nguyên, T.L., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.S., Yasmeen, A., Bismar, T.A., Kirn, D., Falls, T., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. USA 105 (2008), 14981–14986.
77. 77 Forbes, N.E., Krishnan, R., Diallo, J.S., Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front. Oncol., 4, 2014, 191.
78. 78 Diallo, J.S., Boeuf, F.L., Lai, F., Cox, J., Vaha-Koskela, M., Abdelbary, H., Mac Tavish, H., Waite, K., Falls, T., Wang, J., et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18 (2010), 1123–1129.
79. 79 Dornan, M.H., Krishnan, R., Macklin, A.M., Selman, M., El Sayes, N., Son, H.H., Davis, C., Chen, A., Keillor, K., Le, P.J., et al. First-in-class small molecule potentiators of cancer virotherapy. Sci. Rep., 6, 2016, 26786.
80. 80 Naik, S., Russell, S.J., Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin. Biol. Ther. 9 (2009), 1163–1176.
81. 81 Hartono, C., Muthukumar, T., Suthanthiran, M., Immunosuppressive drug therapy. Cold Spring Harb. Perspect. Med., 3, 2013, a015487.
82. 82 Dhar, D., Spencer, J.F., Toth, K., Wold, W.S., Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 83 (2009), 2130–2139.
83. 83 Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R.M., Thompson, J., Selby, P., de Bono, J., Melcher, A., et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res. 14 (2008), 259–269.
84. 84 Peng, K.W., Myers, R., Greenslade, A., Mader, E., Greiner, S., Federspiel, M.J., Dispenzieri, A., Russell, S.J., Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther. 20 (2013), 255–261.
85. 85 Myers, R.M., Greiner, S.M., Harvey, M.E., Griesmann, G., Kuffel, M.J., Buhrow, S.A., Reid, J.M., Federspiel, M., Ames, M.M., Dingli, D., et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther. 82 (2007), 700–710.
86. 86 Salama, A.K.S., Moschos, S.J., Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann. Oncol. 28 (2017), 57–74.
87. 87 Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576.
88. 88 Zhang, X., Sharma, P.K., Goedegebuure, S.P., Gillanders, W.E., Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine 35 (2017), 1094–1100.
89. 89 Kloos, A., Woller, N., Gürlevik, E., Ureche, C.I., Niemann, J., Armbrecht, N., Martin, N.T., Geffers, R., Manns, M.P., Gerardy-Schahn, R., Kühnel, F., PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol. Res. 3 (2015), 751–763.
90. 90 Shen, W., Patnaik, M.M., Ruiz, A., Russell, S.J., Peng, K.W., Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 127 (2016), 1449–1458.
91. 91 Chesney, J., Collichio, F., Andtbacka, R.H., Puzanov, I., Glaspy, J., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., et al. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresectable melanoma. Ann. Oncol. 27 (2016), 379–400.
92. 92 Shim, K.G., Zaidi, S., Thompson, J., Kottke, T., Evgin, L., Rajani, K.R., Schuelke, M., Driscoll, C.B., Huff, A., Pulido, J.S., Vile, R.G., Inhibitory receptors induced by VSV viroimmunotherapy are not necessarily targets for improving treatment efficacy. Mol. Ther., 2017, 10.1016/j.ymthe.2017.01.023 Published online February 22, 2017.
93. 93 Rommelfanger, D.M., Wongthida, P., Diaz, R.M., Kaluza, K.M., Thompson, J.M., Kottke, T.J., Vile, R.G., Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 72 (2012), 4753–4764.
94. 94 Wongthida, P., Diaz, R.M., Pulido, C., Rommelfanger, D., Galivo, F., Kaluza, K., Kottke, T., Thompson, J., Melcher, A., Vile, R., Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. 22 (2011), 1343–1353.
95. 95 Paoloni, M.C., Khanna, C., Comparative oncology today. Vet. Clin. North Am. Small Anim. Pract. 37 (2007), 1023–1032 v.
96. 96 Gentschev, I., Patil, S.S., Petrov, I., Cappello, J., Adelfinger, M., Szalay, A.A., Oncolytic virotherapy of canine and feline cancer. Viruses 6 (2014), 2122–2137.
97. 97 LeBlanc, A.K., Naik, S., Galyon, G.D., Jenks, N., Steele, M., Peng, K.W., Federspiel, M.J., Donnell, R., Russell, S.J., Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum. Gene Ther. Clin. Dev. 24 (2013), 174–181.
98. 98 Sánchez, D., Pelayo, R., Medina, L.A., Vadillo, E., Sánchez, R., Núñez, L., Cesarman-Maus, G., Sarmiento-Silva, R.E., Newcastle disease virus: potential therapeutic application for human and canine lymphoma. Viruses, 8, 2015, 3.
99. 99 Gentschev, I., Patil, S.S., Adelfinger, M., Weibel, S., Geissinger, U., Frentzen, A., Chen, N.G., Yu, Y.A., Zhang, Q., Ogilvie, G., Szalay, A.A., Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 4 (2013), 84–89.
100. 100 Laborda, E., Puig-Saus, C., Rodriguez-García, A., Moreno, R., Cascalló, M., Pastor, J., Alemany, R., A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Mol. Ther. 22 (2014), 986–998.